174 related articles for article (PubMed ID: 25109699)
1. Polymorphisms of HLA-DP are associated with response to peginterferon in Caucasian patients with chronic hepatitis B.
Brouwer WP; Sonneveld MJ; Tabak F; Simon K; Cakaloglu Y; Akarca US; Zeuzem S; Ferenci P; Heathcote JE; de Knegt RJ; Boonstra A; Hansen BE; Janssen HL
Aliment Pharmacol Ther; 2014 Oct; 40(7):811-8. PubMed ID: 25109699
[TBL] [Abstract][Full Text] [Related]
2. Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy.
Tseng TC; Yu ML; Liu CJ; Lin CL; Huang YW; Hsu CS; Liu CH; Kuo SF; Pan CJ; Yang SS; Su CW; Chen PJ; Chen DS; Kao JH
Antivir Ther; 2011; 16(5):629-37. PubMed ID: 21817184
[TBL] [Abstract][Full Text] [Related]
3. Polymorphisms near IL28B and serologic response to peginterferon in HBeAg-positive patients with chronic hepatitis B.
Sonneveld MJ; Wong VW; Woltman AM; Wong GL; Cakaloglu Y; Zeuzem S; Buster EH; Uitterlinden AG; Hansen BE; Chan HL; Janssen HL
Gastroenterology; 2012 Mar; 142(3):513-520.e1. PubMed ID: 22108195
[TBL] [Abstract][Full Text] [Related]
4. HLA-DP and γ-interferon receptor-2 gene variants and their association with viral hepatitis activity in chronic hepatitis B infection.
Lam YF; Wong DK; Seto WK; To KK; Hung IF; Fung J; Lai CL; Yuen MF
J Gastroenterol Hepatol; 2014 Mar; 29(3):533-9. PubMed ID: 23980639
[TBL] [Abstract][Full Text] [Related]
5. Protective effects of HLA-DPA1/DPB1 variants against Hepatitis B virus infection in an Indonesian population.
Wasityastuti W; Yano Y; Ratnasari N; Triyono T; Triwikatmani C; Indrarti F; Heriyanto DS; Yamani LN; Liang Y; Utsumi T; Hayashi Y
Infect Genet Evol; 2016 Jul; 41():177-184. PubMed ID: 27051043
[TBL] [Abstract][Full Text] [Related]
6. Association of IPS1 polymorphisms with peginterferon efficacy in chronic hepatitis B with HBeAg-positive in the Chinese population.
Wang H; Wu H; Bao S; Xiang X; Zhao G; Liu K; Li F; Xu Y; An B; Zhou H; Lu J; Xie Q
Infect Genet Evol; 2015 Apr; 31():161-8. PubMed ID: 25640825
[TBL] [Abstract][Full Text] [Related]
7. Association of HLA-DPA1 and HLA-DPB1 polymorphisms with spontaneous HBsAg seroclearance in Caucasians.
Koukoulioti E; Fischer J; Schott E; Fülöp B; Heyne R; Berg T; van Bömmel F
Liver Int; 2019 Apr; 39(4):646-654. PubMed ID: 30471179
[TBL] [Abstract][Full Text] [Related]
8. A common HLA-DPA1 variant is associated with hepatitis B virus infection but fails to distinguish active from inactive Caucasian carriers.
Vermehren J; Lötsch J; Susser S; Wicker S; Berger A; Zeuzem S; Sarrazin C; Doehring A
PLoS One; 2012; 7(3):e32605. PubMed ID: 22448225
[TBL] [Abstract][Full Text] [Related]
9. No association between IFNL3 (IL28B) genotype and response to peginterferon alfa-2a in HBeAg-positive or -negative chronic hepatitis B.
Wei L; Wedemeyer H; Liaw YF; Chan HL; Piratvisuth T; Marcellin P; Jia J; Tan D; Chow WC; Brunetto MR; Diago M; Gurel S; Morozov V; He H; Zhu Y; Wat C; Surujbally B; Thompson AJ
PLoS One; 2018; 13(7):e0199198. PubMed ID: 30016335
[TBL] [Abstract][Full Text] [Related]
10. IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-α.
Holmes JA; Nguyen T; Ratnam D; Heerasing NM; Tehan JV; Bonanzinga S; Dev A; Bell S; Pianko S; Chen R; Visvanathan K; Hammond R; Iser D; Rusli F; Sievert W; Desmond PV; Bowden DS; Thompson AJ
J Gastroenterol Hepatol; 2013 May; 28(5):861-6. PubMed ID: 23301835
[TBL] [Abstract][Full Text] [Related]
11. Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon.
Boglione L; Cusato J; Allegra S; Esposito I; Patti F; Cariti G; Di Perri G; D'Avolio A
Antiviral Res; 2014 Feb; 102():35-43. PubMed ID: 24316030
[TBL] [Abstract][Full Text] [Related]
12. Presence of precore and core promoter mutants limits the probability of response to peginterferon in hepatitis B e antigen-positive chronic hepatitis B.
Sonneveld MJ; Rijckborst V; Zeuzem S; Heathcote EJ; Simon K; Senturk H; Pas SD; Hansen BE; Janssen HL
Hepatology; 2012 Jul; 56(1):67-75. PubMed ID: 22307831
[TBL] [Abstract][Full Text] [Related]
13. Pegylated-interferon alpha therapy for treatment-experienced chronic hepatitis B patients.
Yeh ML; Peng CY; Dai CY; Lai HC; Huang CF; Hsieh MY; Huang JF; Chen SC; Lin ZY; Yu ML; Chuang WL
PLoS One; 2015; 10(4):e0122259. PubMed ID: 25835020
[TBL] [Abstract][Full Text] [Related]
14. Association of interferon-gamma inducible protein 10 polymorphism with treatment response to pegylated interferon in HBeAg-positive chronic hepatitis B.
Limothai U; Chuaypen N; Khlaiphuengsin A; Posuwan N; Wasitthankasem R; Poovorawan Y; Tangkijvanich P
Antivir Ther; 2016; 21(2):97-106. PubMed ID: 26376789
[TBL] [Abstract][Full Text] [Related]
15. Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean.
Nishida N; Sawai H; Matsuura K; Sugiyama M; Ahn SH; Park JY; Hige S; Kang JH; Suzuki K; Kurosaki M; Asahina Y; Mochida S; Watanabe M; Tanaka E; Honda M; Kaneko S; Orito E; Itoh Y; Mita E; Tamori A; Murawaki Y; Hiasa Y; Sakaida I; Korenaga M; Hino K; Ide T; Kawashima M; Mawatari Y; Sageshima M; Ogasawara Y; Koike A; Izumi N; Han KH; Tanaka Y; Tokunaga K; Mizokami M
PLoS One; 2012; 7(6):e39175. PubMed ID: 22737229
[TBL] [Abstract][Full Text] [Related]
16. Host genetic factors affecting spontaneous HBsAg seroclearance in chronic hepatitis B patients.
Cheng HR; Liu CJ; Tseng TC; Su TH; Yang HI; Chen CJ; Kao JH
PLoS One; 2013; 8(1):e53008. PubMed ID: 23326374
[TBL] [Abstract][Full Text] [Related]
17. Durable hepatitis B surface antigen decline in hepatitis B e antigen-positive chronic hepatitis B patients treated with pegylated interferon-α2b: relation to response and HBV genotype.
Sonneveld MJ; Rijckborst V; Cakaloglu Y; Simon K; Heathcote EJ; Tabak F; Mach T; Boucher CA; Hansen BE; Zeuzem S; Janssen HL
Antivir Ther; 2012; 17(1):9-17. PubMed ID: 22267464
[TBL] [Abstract][Full Text] [Related]
18. Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-e-antigen-positive patients.
Chen CH; Lee CM; Hung CH; Wang JH; Hu TH; Changchien CS; Lu SN
J Gastroenterol Hepatol; 2011 Mar; 26(3):461-8. PubMed ID: 21332543
[TBL] [Abstract][Full Text] [Related]
19. Vitamin D-Binding protein Gene Polymorphism Predicts Pegylated Interferon-Related HBsAg Seroclearance in HBeAg-Negative Thai Chronic Hepatitis B Patients: A Multicentre Study.
Thanapirom K; Suksawatamnuay S; Sukeepaisarnjaroen W; Treeprasertsuk S; Tanwandee T; Charatcharoenwitthaya P; Thongsawat S; Leerapun A; Piratvisuth T; Boonsirichan R; Bunchorntavakul C; Pattanasirigool C; Pornthisarn B; Tuntipanichteerakul S; Sripariwuth E; Jeamsripong W; Sanpajit T; Poovorawan Y; Komolmit P
Asian Pac J Cancer Prev; 2019 Apr; 20(4):1257-1264. PubMed ID: 31030503
[TBL] [Abstract][Full Text] [Related]
20. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa.
Buster EH; Hansen BE; Lau GK; Piratvisuth T; Zeuzem S; Steyerberg EW; Janssen HL
Gastroenterology; 2009 Dec; 137(6):2002-9. PubMed ID: 19737568
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
